BioSpace News Archive

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with a robust pipeline of novel investigational therapeutics built on protein dysregulation expertise, today announced that the Company has earned a $60 million milestone from its worldwide collaboration with Roche based on the first patient dosed in the Phase 2b PADOVA study of prasinezumab in patients with early Parkinson’s disease

Shockwave Medical, Inc., a pioneer in the development and commercialization of Intravascular Lithotripsy to treat complex calcified cardiovascular disease, reported financial results for the three months ended March 31, 2021.

SeaSpine Holdings Corporation, a global medical technology company focused on surgical solutions for the treatment of spinal disorders, announced the Company will present at the Canaccord Genuity Virtual Musculoskeletal Conference on Thursday, May 20, 2021, beginning at 1:00 PM ET.

FibroGen, Inc. (NASDAQ: FGEN) today reported financial results for the first quarter 2021 and provided an update on the Company’s recent developments.

InnovAge Holding Corp. (the “Company” or “InnovAge”) (Nasdaq: INNV), a market leading healthcare delivery platform for high-cost, dual-eligible seniors, announced financial results for its fiscal third quarter ended March 31, 2021.

Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company focused on redefining drug discovery by identifying allosteric sites that have never been targeted previously and discovering molecules that can bind stabilize and restore functional activity to misfolded enzymes, today announced its financial results as of and for the first quarter ended March 31, 2021 and provided a corporate update.

Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today provided a corporate update and reported financial results for the first quarter ended March 31, 2021.

Biogen Inc. (Nasdaq: BIIB) and Capsigen Inc. announced today that they have entered into a strategic research collaboration to engineer novel adeno-associated virus (AAV) capsids that have the potential to deliver transformative gene therapies that address the underlying genetic causes of various CNS and neuromuscular disorders.

Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs), today announced financial results and operational highlights for the first quarter ended March 31, 2021.

Vir Biotechnology, Inc. reminds stockholders that it will hold its 2021 Annual General Meeting of Stockholders on Thursday, May 20, 2021, at 11:30 a.m. PT.